Subjective, Behavioral and Physiological Responses to Intravenous Meperidine in Healthy Volunteers
Overview
Affiliations
Meperidine is a mu opiate agonist that is frequently used to treat pain. We examined in healthy volunteers (N = 10) the effects of intravenous meperidine (0, 0.25, 0.5, and 1.0 mg/kg) on mood and psychomotor performance. A randomized, placebo-controlled, crossover design was used in which subjects were injected with meperidine or saline in a double-blind fashion. Subjects completed several subjective effects questionnaires commonly used in abuse liability testing studies before drug injection and at periodic intervals for up to 5 h after drug injection. Subjects also completed several psychomotor tests. Meperidine produced a constellation of subjective effects in a dose-related fashion, including increases in ratings of "sedated," "coasting or spaced out" and "feel drug effect" ratings. Many of the drug's subjective effects persisted up to 4 or 5 h after administration of the 1.0 mg/kg dose. Drug liking ratings assessed on a visual analog scale were increased after meperidine injection in about half of the subjects (P = 0.09). Eye-hand coordination was affected slightly by meperidine but other indices of psychomotor functioning were unaffected. Miosis increased in a dose-related fashion. Other physiological parameters, such as vital signs, were not affected by meperidine. We conclude that meperidine in healthy volunteers has robust and long-lasting effects on mood, but may have weaker effects on psychomotor performance.
Opioid Use and Driving Performance.
Cameron-Burr K, Conicella A, Neavyn M J Med Toxicol. 2021; 17(3):289-308.
PMID: 33403571 PMC: 8206443. DOI: 10.1007/s13181-020-00819-y.
The role of the opioid system in decision making and cognitive control: A review.
van Steenbergen H, Eikemo M, Leknes S Cogn Affect Behav Neurosci. 2019; 19(3):435-458.
PMID: 30963411 PMC: 6599188. DOI: 10.3758/s13415-019-00710-6.
Fliegert F, Kurth B, Gohler K Eur J Clin Pharmacol. 2005; 61(4):257-66.
PMID: 15906019 DOI: 10.1007/s00228-005-0920-y.
Zacny J, Gutierrez S Psychopharmacology (Berl). 2003; 170(3):242-254.
PMID: 12955305 DOI: 10.1007/s00213-003-1540-9.
Azolosa J, Stitzer M, Greenwald M Psychopharmacology (Berl). 1994; 114(1):71-80.
PMID: 7846209 DOI: 10.1007/BF02245446.